153 related articles for article (PubMed ID: 31683059)
1. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.
Liu Z; Mao X; Wu J; Yu K; Yang Q; Suo C; Lu M; Jin L; Zhang T; Chen X
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1906-1914.e25. PubMed ID: 31683059
[TBL] [Abstract][Full Text] [Related]
2. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
Liu Z; Mao X; Yu K; Suo C; Jin L; Zhang T; Chen X
J Viral Hepat; 2020 Jun; 27(6):585-592. PubMed ID: 32049405
[TBL] [Abstract][Full Text] [Related]
4. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Lawitz EJ; Dvory-Sobol H; Doehle BP; Worth AS; McNally J; Brainard DM; Link JO; Miller MD; Mo H
Antimicrob Agents Chemother; 2016 Sep; 60(9):5368-78. PubMed ID: 27353271
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
[No Abstract] [Full Text] [Related]
7. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
[TBL] [Abstract][Full Text] [Related]
8. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank.
Sharafi H; Ghalamkari S; Hassanshahi A; Alavian SM
Microb Drug Resist; 2019 Sep; 25(7):1072-1079. PubMed ID: 31021305
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia.
Isakov V; Hedskog C; Wertheim JO; Hostager RE; Parhy B; Schneider AB; Suri V; Mo H; Geivandova N; Morozov V; Bessonova E; Gankina N; Zhdanov K; Abdurakhmanov D; Svarovskaia E
Int J Infect Dis; 2021 Dec; 113():36-42. PubMed ID: 34560266
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A; Sorbo MC; Aragri M; Lenci I; Teti E; Polilli E; Di Maio VC; Gianserra L; Biliotti E; Masetti C; Magni CF; Babudieri S; Nicolini LA; Milana M; Cacciatore P; Sarmati L; Pellicelli A; Paolucci S; Craxì A; Morisco F; Palitti VP; Siciliano M; Coppola N; Iapadre N; Puoti M; Rizzardini G; Taliani G; Pasquazzi C; Andreoni M; Parruti G; Angelico M; Perno CF; Cento V; Ceccherini-Silberstein F;
Sci Rep; 2018 Jun; 8(1):8988. PubMed ID: 29895871
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
[TBL] [Abstract][Full Text] [Related]
12. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
13. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
[TBL] [Abstract][Full Text] [Related]
15. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Wei L; Omata M; Lim YS; Xie Q; Hou JL; Jia J; Hedskog C; Martin R; Doehle B; Yang J; De-Oertel S; Massetto B; Kersey K; Brainard DM; Svarovskaia E; Mo H; Han KH; Mizokami M; Duan Z
Antiviral Res; 2018 Oct; 158():178-184. PubMed ID: 30120954
[TBL] [Abstract][Full Text] [Related]
16. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank.
Sharafi H; Maleki S; Alavian SM
Virus Res; 2019 Jan; 259():54-61. PubMed ID: 30401643
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
[TBL] [Abstract][Full Text] [Related]
19. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours.
Nguyen T; Valantin MA; Delaugerre C; Amiel C; Netzer E; L'Yavanc T; Ohayon M; Valin N; Day N; Kreplak G; Pialoux G; Calvez V; Molina JM; Marcelin AG; Todesco E
J Glob Antimicrob Resist; 2021 Mar; 24():311-315. PubMed ID: 33540082
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
